Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relative age effect

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    642 result(s) found for: Relative age effect. Displaying page 3 of 33.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-005435-75 Sponsor Protocol Number: U1111-1261-1912 Start Date*: 2022-07-21
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity
    Medical condition: Obesity, Overweight
    Disease: Version SOC Term Classification Code Term Level
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001671-79 Sponsor Protocol Number: CAIN457ADE08 Start Date*: 2018-02-15
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, multicenter 28 week study to compare the efficacy and safety of combining Cosentyx (Secukinumab) (4-weekly, 300 mg s.c.) with a lifestyle intervention to Cosentyx therapy alone in adu...
    Medical condition: Moderate to severe plaque type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006224-40 Sponsor Protocol Number: AxGD Start Date*: Information not available in EudraCT
    Sponsor Name:Instytut ,,Pomnik-Centrum Zdrowia Dziecka"
    Full Title: Evaluation of the safety and efficacy of ambroxol (ABX) use in Polish patients with Gaucher disease, presenting neuronopathic type (GD type III, GD3) resulting from homozygous c.1448T>C mutation (p...
    Medical condition: Gaucher disease
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001788-21 Sponsor Protocol Number: CRTH258C2302 Start Date*: 2019-06-06
    Sponsor Name:Novartis Pharma AG
    Full Title: An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multi center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment du...
    Medical condition: Central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Prematurely Ended) HU (Completed) NL (Prematurely Ended) GR (Prematurely Ended) FI (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011755-47 Sponsor Protocol Number: 2007-001 Start Date*: 2009-07-06
    Sponsor Name:Vivostat A/S
    Full Title: A feasibility study to evaluate the effect of Vivostat® Platelet Rich Fibrin (PRF®) in the treatment of diabetic foot ulcers
    Medical condition: - Diabetic foot ulcers Texas Grade I placed at or below the anchle -Non-ischaemic, non-infected ulcers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000455-39 Sponsor Protocol Number: C21-109-09 Start Date*: 2021-04-09
    Sponsor Name:Pharma Holdings AS
    Full Title: A double-blind, placebo-controlled, interventional parallel group study to evaluate the antiviral effect of a single nasal application of LTX-109 3% gel, in comparison to placebo gel, in subjects w...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003677-66 Sponsor Protocol Number: RESTORE Start Date*: 2022-02-14
    Sponsor Name:Amsterdam University Medical Center
    Full Title: Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis
    Medical condition: Multiple sclerosis (MS) Internuclear ophthalmoparesis (INO)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080865 Multiple sclerosis lesion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005211-32 Sponsor Protocol Number: DS1040-B-U107 Start Date*: 2017-03-08
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of DS-1040b when Added to ...
    Medical condition: DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including Pulmonary Embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037379 Pulmonary embolism and thrombosis HLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000961-19 Sponsor Protocol Number: 2019/376 Start Date*: 2019-08-26
    Sponsor Name:Helse Fonna
    Full Title: “Haemodynamic stability during induction of general anesthesia with propofol and remifentanil: A randomized, controlled, double-blind study comparing medium and low remifentanil doses.”
    Medical condition: In daily clinical work we observe a hypotensive effect and a reduction in heart rate when induction of general anesthesia is performed using propofol and remifentanil. It is difficult to differenti...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000958-56 Sponsor Protocol Number: 2019/375 Start Date*: 2019-08-16
    Sponsor Name:Helse Fonna
    Full Title: “Haemodynamic stability during induction of general anesthesia with propofol and remifentanil: A randomized, controlled, double-blind study comparing low vs high propofol doses.”
    Medical condition: In daily clinical work we observe a hypotensive effect and a reduction in HR when induction of general anesthesia is performed using propofol and remifentanil. It is difficult to differentiate the ...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000436-62 Sponsor Protocol Number: GS-US-380-4547 Start Date*: 2021-02-12
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A Phase 1, Single-Dose, Cross-Over Study Evaluating the Relative Bioavailability and Food Effect of a Pediatric Tablet for Oral Suspension of Bictegravir/Emtricitabine/Tenofovir Alafenamide and the...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-001152-42 Sponsor Protocol Number: ShaperonC002 Start Date*: 2022-09-05
    Sponsor Name:Shaperon, Inc.
    Full Title: A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID...
    Medical condition: COVID-19 Pneumonia Patients
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) HR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002109-24 Sponsor Protocol Number: E2007-J000-335 Start Date*: 2020-06-17
    Sponsor Name:Eisai Co., Ltd.
    Full Title: A Double-blind, Placebo-controlled, Parallel-group Study With an Openlabel Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subject...
    Medical condition: Refractory Partial-onset Seizures
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004742-23 Sponsor Protocol Number: CRTH258B2301 Start Date*: 2018-09-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to D...
    Medical condition: diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003110-14 Sponsor Protocol Number: MK-0859-021 Start Date*: 2012-12-03
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or W...
    Medical condition: Hypercholesterolemia or Low HDL-C
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) DE (Completed) HU (Completed) ES (Completed) SK (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-002262-12 Sponsor Protocol Number: DAPA-OB Start Date*: 2021-05-17
    Sponsor Name:Hospital Universitari Germans Trias i Pujol
    Full Title: "Effect of dapagliflozin on glomerular hyperfiltration in nondiabetic obese patients with or without treatment with ACEIs". Pilot clinical trial of efficacy, low level of intervention, unicentric, ...
    Medical condition: This study aims to demonstrate the hypothesis that treatment with dapagliflozin 10mg lowers in at least 10-20% of measured glomerular filtration rate (mGFR) in non-diabetic obese patients with glom...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024256-28 Sponsor Protocol Number: 28431754DIA2003 Start Date*: 2011-05-25
    Sponsor Name:Janssen Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2...
    Medical condition: Subjects with T2DM with inadequate glycemic control on a maximally effective dose of metformin in monotherapy
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-007687-41 Sponsor Protocol Number: CARISEPY3013 Start Date*: 2009-02-17
    Sponsor Name:Janssen Cilag International, NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial On...
    Medical condition: Epilepsy with partial onset seizures
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015037 Epilepsy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004130-14 Sponsor Protocol Number: IMA 04001 Start Date*: 2005-02-17
    Sponsor Name:Biogen Idec GmbH
    Full Title: A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with r...
    Medical condition: Male and female subjects with relapsing multiple sclerosis previously treated with interferon beta-1a (22 mcg or 44 mcg, SC three times a week).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000365-12 Sponsor Protocol Number: CAFQ056A2166 Start Date*: 2011-04-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label, five period, crossover study to evaluate the single dose pharmacokinetics and food effect of two pediatric AFQ056 formulations in healthy adults
    Medical condition: Not Applicable. This is a PK study (including evaluation of food effect).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 11 17:04:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA